Table 6.
AEs in the groups.
| Total, N = 86 | Control group, N = 43 | CHM group, N = 43 | ||
|---|---|---|---|---|
| No. (%) | No. (%) | No. (%) | p | |
| Any Aes | 50 (58%) | 22 (51%) | 28(65%) | 0.274 |
| Increased D-dimer | 19(22%) | 5 (12%) | 14(33%) | 0.036 |
| Dyspnea | 14 (16%) | 5 (12%) | 9 (21%) | 0.382 |
| Fever | 7 (8%) | 3 (7%) | 4 (9%) | 1.000 |
| Increased alanine aminotransferase | 6 (7%) | 1 (2%) | 5 (12%) | 0.202 |
| Diarrhea | 6 (7%) | 2 (5%) | 4 (9%) | 0.676 |
| Increased aspartate aminotransferase | 5 (6%) | 1 (2%) | 4 (9%) | 0.360 |
| Decreased peripheral oxygen saturation | 4 (5%) | 4 (9%) | 0 (0%) | 0.116 |
| Constipation | 4 (5%) | 1 (2%) | 3 (7%) | 0.616 |
| Chest tightness | 3 (4%) | 0 (0%) | 3 (7%) | 0.241 |
| Cough | 3 (4%) | 0 (0%) | 3 (7%) | 0.241 |
| Skin rash | 3 (4%) | 0 (0%) | 3 (7%) | 0.241 |
| Increased neutrophil percentage | 3 (4%) | 3 (7%) | 0 (0%) | 0.241 |
| Increased whitecell count | 2 (2%) | 1 (2%) | 1 (2%) | 1.000 |
| Thrombocytopenia | 2 (2%) | 1 (2%) | 1 (2%) | 1.000 |
| Melena | 2 (2%) | 1 (2%) | 1 (2%) | 1.000 |
| Fatigue | 2 (2%) | 1 (2%) | 1 (2%) | 1.000 |
| Sleep disorders | 2 (2%) | 1 (2%) | 1 (2%) | 1.000 |
| Urination disorder | 2 (2%) | 1 (2%) | 1 (2%) | 1.000 |
| Palpitation | 2 (2%) | 0 (0%) | 2 (5%) | 0.494 |
| Chest pain | 2 (2%) | 0 (0%) | 2 (5%) | 0.494 |
| Pruritus | 2 (2%) | 0 (0%) | 2 (5%) | 0.494 |
| Dysphoria | 2 (2%) | 2 (5%) | 0 (0%) | 0.494 |
| Hemoptysis | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Nausea and vomiting | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Abdominal discomfort | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Anorexia | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Headache and ophthalmodynia | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Oral ulcer | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Lymphopenia | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased C-reactive protein | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased NTproBNP | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Atrial fibrillation | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Hypoalbuminemia | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Hyponatremia | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased glutamyl transpeptidase | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased creatinine | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased creatine kinase | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased lactate dehydrogenase | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Increased urea nitrogen | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Costalgia | 1 (1%) | 1 (2%) | 0 (0%) | 1.000 |
| Serious Aes | 5 (6%) | 2 (5%) | 3 (7%) | 1.000 |
| Respiratory failure | 2 (2%) | 0 (0%) | 2 (5%) | 0.494 |
| Shock | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Severe metabolic acidosis | 1 (1%) | 0 (0%) | 1 (2%) | 1.000 |
| Unconsciousness | 2 (2%) | 2 (5%) | 0 (0%) | 0.494 |
AE: Adverse event; NTproBNP: N-terminal prohormone of brain natriuretic peptide.